Estradiol/nomegestrol monophasic - Merck & co.
Alternative Names: E2-Nomac monophasic; E2/Nomac monophasic; EMM-310066; IOA; MK-8175A; NOMAC-E2; Nomac-E2 monophasic; NOMAC/E2; Nomac/E2 monophasic; Nomegestrol acetate/17 beta-estradiol; Nomegestrol acetate/estradiol; Nomegestrol/estradiol; Org 10486-0/Org 2317; SCH 900121; ZoelyLatest Information Update: 29 Oct 2021
Price :
$50 *
At a glance
- Originator Theramex SAM
- Developer Merck & Co
- Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 29 Oct 2021 Launched for Pregnancy (Prevention) in Ukraine, Colombia, Turkey, Austria, Germany, Italy, Russia (PO)
- 17 Sep 2020 Theramex and Consilient Health collaborate to distribute Estradiol/nomegestrol (Zoely®) in Ireland and Nordic countries
- 24 Jan 2020 Theramex to acquire further commercial rights to estradiol/nomegestrol monophasic for Pregnancy (Prevention)